



## *MolMed and Takara Bio agreed on terminating the license agreement on TK therapy in Asian countries*

Milan (Italy), March 31, 2016 – MolMed S.p.A. (MLM.MI) and Takara Bio Inc. (“Takara”) (OTCPK:TKBIF), today agreed on discontinuing their long lasting collaboration on TK (Zalmoxis®) by terminating all the related agreements, as Takara has not been able to produce the results planned by MolMed for the development and commercialization of the TK therapy in Asian countries.

In particular, the termination concerns the “Master Licence Agreement” that MolMed and Takara signed in 2003, under which MolMed granted Takara an exclusive license on MolMed’s know-how, data materials and patents related to TK.

Pursuant to the terms of this termination agreement, MolMed will regain all commercial rights of Zalmoxis® in Asian territories that could further be transferred to other third parties with no outstanding obligations to Takara. The parties owe no outstanding royalties and any payment settled under the agreements prior to termination date, shall not be reimbursable.

Riccardo Palmisano, CEO of MolMed S.p.A. commented: *“Today’s decision is in line with our plan of bringing Zalmoxis® to the market, including an important territory such as Asia, in the shortest possible time. Our search for a new experienced and committed partner that could contribute to the successful clinical development and to the commercialization of Zalmoxis® (TK) in the Asian markets is already underway”.*

---

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14.5.1999, as subsequently amended.

### *About Takara Bio Inc.*

Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin® reagent, which is a world-standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology including functional food and mushroom production businesses; and is committed preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. More information is available at <http://www.takara-bio.com>.

### *About MolMed*

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, currently in Phase III in high-risk acute leukaemia and under evaluation by EMA for a Conditional Marketing Authorization; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the tumour mass, currently investigated in a broad clinical programme; CAR-CD44v6, an immuno-gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed has its headquartered at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and a local unit at OpenZone, in Bresso (Milan). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI). More information is available at [www.molmed.com](http://www.molmed.com)

### *For further information*

#### *MolMed:*

Laura Villa

#### *Investor Relations & Communication Director*

phone: +39 02 21277.205

e-mail: [investor.relations@molmed.com](mailto:investor.relations@molmed.com)

#### *Press agent*

#### **Federico Ferrari**

SEC Relazioni Pubbliche e Istituzionali s.r.l.

phone: +39 02 6249991 – mobile +39 347 6456873

e-mail: [ferrari@secrp.it](mailto:ferrari@secrp.it)

#### **DISCLAIMER**

*This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.*